Skip to main content

Drug Interaction Report

2 potential interactions and/or warnings found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Moderate

propofol nitrous oxide

Applies to: Diprivan (propofol), nitrous oxide

ADJUST DOSE: Premedication with morphine (0.15 mg/kg) and nitrous oxide (67% in oxygen) has been shown to decrease maintenance infusion rates of propofol relative to infusion rates required with nonnarcotic premedication (e.g., lorazepam).

MANAGEMENT: If morphine and nitrous oxide are used as premedications, the rate of propofol infusion should be adjusted according to the patient's clinical response.

References (3)
  1. (2001) "Product Information. Diprivan (propofol)." Astra-Zeneca Pharmaceuticals
  2. Pavlin DJ, Coda B, Shen DD, et al. (1996) "Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers." Anesthesiology, 84, p. 23-37
  3. (2024) "Product Information. propOFol Lipuro (B Braun) (propOFol)." B Braun Australia Pty Ltd, 3

Drug and food interactions

Moderate

propofol food

Applies to: Diprivan (propofol)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.